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Stage at diagnosis and cancer survival for
Indigenous Australians in the Northern Territory
John R Condon, Tony Barnes, Bruce K Armstrong, Sid Selva-Nayagam and J Mark Elwood

C

ancer mortality rates are higher for
Indigenous Australians than for other
Australians for many specific cancer
sites. This is partly because of the higher
incidence of some cancers (particularly lung
and other smoking-related cancers, cervical
and liver cancers), and partly because of
lower survival for most cancers.1-3
Lower cancer survival rates for Indigenous people compared with non-Indigenous
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the Northern
Territory
(for
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cancers
examined).3 Survival rates have not
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been Research
reported for Indigenous people elsewhere in Australia.
In South Australia, Indigenous people
were more likely to have advanced disease at
diagnosis than non-Indigenous people (for
all cancers combined), but this explained
only part of the difference in survival.4 Stage
at diagnosis has not been reported for Indigenous people elsewhere in Australia, or for
individual cancer sites.
Our study investigated whether, in the
Northern Territory (NT), Indigenous people
with cancer had more advanced disease at
diagnosis than non-Indigenous people with
cancer, and whether later diagnosis explains
their lower cancer survival.
METHODS
All residents of the NT diagnosed with cancers of the colon and rectum (including
anus), lung, female breast, cervix or nonHodgkin lymphoma in 1991–2000 were eligible for inclusion in this study. These five
cancers were chosen as they are designated
“priority” cancers in Australia, and as there
were sufficient numbers of both Indigenous

ABSTRACT
Objective: To investigate whether Indigenous Australians with cancer have more
advanced disease at diagnosis than other Australians, and whether late diagnosis
explains lower Indigenous cancer survival rates.
Design: Retrospective cohort study.
Setting and participants: Indigenous and non-Indigenous people diagnosed with
cancers of the colon and rectum, lung, breast or cervix and non-Hodgkin lymphoma in
the Northern Territory of Australia in 1991–2000.
Main outcome measures: SEER summary stage of cancer at diagnosis (local, regional
or distant spread), cause-specific cancer survival rates and relative risk of cancer death.
Results: Diagnosis with advanced disease (regional or distant spread) was more
common for Indigenous people (70%; 95% CI, 62%–78%) than for non-Indigenous
people (51%; 95% CI, 53%–59%) with cancers of the colon and rectum, breast, cervix and
non-Hodgkin lymphoma, but for lung cancer the opposite was found (Indigenous, 56%
[95% CI, 46%–65%] v non-Indigenous, 69% [95% CI, 64%–75%]). Stage-adjusted survival
rates were lower for Indigenous people for each cancer site. With few exceptions, the
relative risk of cancer death was higher for Indigenous people for each category of stage
at diagnosis for each cancer site.
Conclusions: Health services apparently could, and should, be performing better for
Indigenous people with cancer in the Northern Territory, and probably elsewhere in
Australia. This study has demonstrated that data from cancer registers, enhanced with
data on stage at diagnosis, can be used to monitor health service performance for
Indigenous Australians in the Northern Territory; similar data is available in other States,
and could be used to monitor health service performance for Indigenous people
throughout Australia.
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and non-Indigenous cases to enable comparison. Cases were identified from the NT Cancer Registry. 5, 6 Hospital and private
specialists’ medical records were examined to
collect data on stage at diagnosis and to verify
data obtained from the Registry, including
Indigenous status and cause of death.
Cancer staging
Cancer stage at diagnosis was classified
using the SEER summary staging system.7
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This staging system was used as it is the only
system that applies to all five cancers
included in the study. It classifies cancers as
localised, regional or distant spread. Cancer
stage was also classified using the TNM
staging system (except for non-Hodgkin
lymphoma, to which TNM staging does not
apply) and site-specific staging systems
(Dukes for colorectal cancer, FIGO for cervical cancer and Ann Arbor for non-Hodgkin
lymphoma); results for these systems were
published elsewhere.8
Statistical analysis
The proportion of Indigenous and nonIndigenous people with advanced disease
(regional or distant spread), adjusted for age
at diagnosis, was compared for each of the
five cancers.
For each cancer, Cox regression analysis
was used to estimate the stage-specific and
stage-adjusted hazard ratios (relative risks of
cancer death) and their 95% confidence
277
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1 Number of cases and proportion with advanced disease* at diagnosis among
people diagnosed with cancer in the Northern Territory, 1991–2000
Total cases†
Cancer site
Colon and rectum

Proportion with advanced disease (95% CI)‡

NonIndigenous Indigenous

Indigenous

NonIndigenous

P§

89% (80%–99%)

68% (62%–83%)

0.05

summary stage at diagnosis for 1201 people
(99.4% of those for whom medical records
were available). Five of the seven patients
for whom stage at diagnosis could not be
determined were non-Indigenous (two with
colorectal cancer, one with lung cancer, and
two with breast cancer), and two were
Indigenous (both with lung cancer).

34

268

Lung

109

258

56% (46%–65%)

69% (64%–75%)

0.02

Breast

44

315

55% (40%–70%)

38% (33%–44%)

0.04

Cancer stage at diagnosis

Cervix

40

55

37% (21%–52%)

24% (13%–35%)

0.19

Non-Hodgkin
lymphoma

16

62

91% (76%–100%)

65% (53%–76%)

0.05

Indigenous people with cancer of the colon
and rectum, breast, cervix, and non-Hodgkin lymphoma, were more likely to be diagnosed with advanced disease than nonIndigenous people, although the difference
was not always statistically significant (Box
1). For all four cancers combined (adjusted
for cancer site and age at diagnosis), 70% of
Indigenous people were diagnosed with
advanced disease (95% CI, 62%–78%) compared with 51% of non-Indigenous people
(95% CI, 53%–59%).
For lung cancer, Indigenous people were
less likely than non-Indigenous people to be
diagnosed with advanced disease (Box 1).

* Regional or distant spread of disease.
† Number of cases with known stage for each cancer site.
‡ Number of cases with regional or distant spread of disease at diagnosis as a proportion of the total number
of cases with known stage, for each cancer site, adjusted for age at diagnosis to the age distribution of nonIndigenous cases.
§ Test for difference between proportions of Indigenous and non-Indigenous patients with advanced disease,
adjusted for age at diagnosis.

2 Relative risk (RR) of cancer death for Indigenous versus non-Indigenous
patients by cancer site and stage at diagnosis
Age-adjusted RR (95% CI)
Cancer site
Colon and rectum
Lung

Localised

Regional

Distant

Age- and stageadjusted RR
(95% CI)

na

6.9 (3.6–13.1)

2.0 (0.8–4.6)

6.5 (3.7–11.3)

1.4 (0.9–2.1)

1.8 (1.1–3.0)

0.8 (0.5–1.2)

1.4 (1.1–1.8)

Breast

2.1 (0.5–9.3)

2.7 (1.2–6.4)

2.7 (0.8–9.5)

2.4 (1.1–5.2)

Cervix

2.1 (0.7–6.0)

6.5 (1.7–25.5)

na

3.0 (1.4–6.2)

na

2.5 (0.5–12.2)

8.5 (2.9–24.4)

5.2 (2.2–11.9)

Non-Hodgkin
lymphoma

na = not available: there were insufficient numbers of cancer deaths to estimate relative risks in these
categories.

intervals for Indigenous compared with nonIndigenous people. Follow-up for death was
to 31 December 2002. Stage-adjusted, causespecific cancer survival rates were also estimated from regression models. All regression
analyses included adjustment for age at diagnosis by individual year of age.
Because of empirical evidence for the
existence of important interacting effects,
regression models used to estimate stagespecific hazard ratios included an interaction term for Indigenous status by age at
diagnosis. Models used to estimate stageadjusted hazard ratios also included interaction terms for Indigenous status by stage
and age by stage. Cox regression analysis of
cause-specific relative risk of cancer death
was used to analyse cancer survival rather
than relative survival because of the complexity of these interactions. For the same
reason, the contribution of diagnosis with
more advanced disease to lower Indigenous
278

cancer survival could not be validly assessed
by comparing survival rates before and after
adjustment for stage at diagnosis. A more
detailed report of both analytical methods
and results is available elsewhere.8
The study was approved by the Menzies
School of Health Research Human Research
Ethics Committee (HREC), the Charles Darwin University HREC and the Central Australian HREC.
RESULTS
We found that 1373 people were eligible for
inclusion; medical records containing details
of cancer diagnosis and treatment could not
be found for 165 of these, including 32 who
were recorded by the NT Cancer Registry as
Indigenous. This left 1208 participants in
the study (88% of those eligible).
Sufficient information was found in medical records to enable classification of SEER
MJA • Volume 182 Number 6 • 21 March 2005

Cancer survival rates
With one exception (lung cancer with distant spread), the relative risk of cancer
death, adjusted for age at diagnosis, was
greater for Indigenous than for non-Indigenous people in each category of stage at
diagnosis for each cancer site, although not
all 95% confidence intervals excluded 1.0
(Box 2). The stage-adjusted relative risk of
cancer death was significantly greater in
Indigenous than non-Indigenous people for
each cancer site.
These differences were reflected in a lower
age- and stage-adjusted 5-year cause-specific cancer survival rate in Indigenous people compared with non-Indigenous people
for each cancer site (Box 3).
DISCUSSION
Between 1991 and 2000 in the NT, Indigenous people with cancer of the colon and
rectum, breast, cervix and non-Hodgkin
lymphoma were more likely to be diagnosed
with advanced disease than non-Indigenous
people. Only for cancer of the lung were
Indigenous people less likely to be diagnosed with advanced disease than nonIndigenous people.
Cancer survival was lower for Indigenous
patients than non-Indigenous patients for all
five cancer sites examined and, with few
exceptions, for each stage at diagnosis for
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3 Adjusted cause-specific 5-year
cancer survival rates,* by cancer
site and Indigenous status
Site

NonIndigenous Indigenous

Colon and rectum

55.0%

30.7%

Lung

11.5%

5.2%

Breast

83.7%

67.5%

Cervix

70.0%

27.1%

Non-Hodgkin
lymphoma

65.2%

16.3%

* Derived from Cox regression models, adjusted for
age at diagnosis and stage at diagnosis;
confidence intervals could not be calculated.

each cancer site. Thus while the more
advanced cancer stage at diagnosis in Indigenous patients for four of the five cancer sites
may explain part of their poorer survival
from cancer, it is unlikely to explain it all.
Although up to 12 years had elapsed
between diagnosis and data collection, all
but 165 records were available (12% of
eligible cases). Including these additional
cases could have changed the results of the
study to only a small extent. A data-quality
audit of the Registry for cases diagnosed in
the period 1991–1999 estimated that completeness of case ascertainment was about
94%.6 A recent project by the Registry to
identify previously unregistered cases
increased the number of registered cases
diagnosed in 1991–1999 by 3%.6 These
additional cases were not included in this
study, but would have made little difference
to the results reported here.
The degree of misclassification of Indigenous status was small. A data-quality audit
of the NT Cancer Registry estimated that
about 15% of Indigenous people in the
Registry were misclassified as non-Indigenous;6 this was reduced to about 12% for
people included in this study after examination of their medical records during data
collection. We have no data from which to
estimate the effect of Indigenous underidentification on the difference between
Indigenous and non-Indigenous cancer survival rates. Bias in either direction could be
argued.
Cause-specific survival analysis relies on
the accuracy of recording of cause of death,
to differentiate cancer deaths from noncancer deaths. Cause of death was verified
during examination of medical records,
rather than relying on death registration
data recorded by the Cancer Registry. Cause-

specific analysis was also found to give
similar results to relative survival analysis
(not reported here).
Our finding that a higher proportion of
Indigenous people had localised lung cancer
compared with non-Indigenous people is
inconsistent with the findings for the other
four cancer sites. Indigenous people in the
NT have very high prevalence of chronic
respiratory disease and a high incidence of
tuberculosis; consequently, they may have
more frequent chest x-rays and other investigations as part of clinical management or
long-term follow-up and contact tracing by
the tuberculosis control program.9,10 This
might explain why they are more likely to
be diagnosed with early-stage disease. Alternatively, the proportion of Indigenous people with regional disease at diagnosis may
have been underestimated if Indigenous
patients with lung cancer were less likely to
have intensive investigations, such as mediastinoscopy, thoracoscopy and exploratory
thoracotomy.
A reason that Indigenous people with
cancer had a later stage at diagnosis and
lower survival rates could be that all five
cancers are more “aggressive” in Indigenous
people, either because there is something
different about the biology of these cancers
in Indigenous people or because Indigenous
people are more susceptible to rapid cancer
spread. However, the distribution of histological grade was similar in Indigenous and
non-Indigenous people for all five cancer
sites.8 There was also little difference in
morphological type, except in colorectal
cancer, which was more likely to be squamous cell carcinoma in Indigenous people.8
It is much more likely that more advanced
disease at diagnosis in Indigenous people is
due to late diagnosis, possibly because of
low awareness of potentially dangerous early
symptoms and tardiness in seeking medical
advice, poor access to or low quality of
primary care, diagnostic or specialist services, or reluctance to seek attention when
symptoms cause concern because of nihilistic beliefs about cancer and the chance of
cure.11-13 For breast and cervical cancer, low
participation of Indigenous women in
screening programs may also be involved.14
The 5-year cancer survival rates in nonIndigenous people were similar to those for
Australia as a whole for cancer diagnosed in
1992–1997: colon cancer, 61.6%; rectal
cancer, 59.7%; lung cancer, 14.2%; breast
cancer, 83.3%; cervical cancer, 76.3%; nonHodgkin lymphoma, 69.3% (Australian
rates adjusted to the age and sex distribution
MJA • Volume 182 Number 6 • 21 March 2005

of NT Indigenous cases, from the Australian
Institute of Health and Welfare15). While
this comparison is not exact, because of the
different methods used to estimate survival
rates (relative survival for Australian rates,
and regression-modelled cause-specific survival for NT non-Indigenous rates), it does
suggest that NT cancer services can perform
at near to national levels for non-Indigenous
patients.
Although SEER summary staging is not as
detailed as staging by other systems, comparison of stage-adjusted hazard ratios
using summary staging and more detailed
staging indicated that summary staging provided effective adjustment for stage at diagnosis (results not shown). Lower stageadjusted cancer survival in Indigenous people may be due to choices against more
aggressive, curative treatment (particularly
if treatment requires interstate travel);
delayed or incomplete treatment; or factors
which make Indigenous people more susceptible to the life-threatening complications of cancer treatment. The latter could
include presence of other chronic diseases;
heavy alcohol and tobacco consumption;
and poor housing and environmental conditions, which increase the risk of infectious
diseases during and after chemotherapy and
radiotherapy.16,17
Our results suggest that health services
apparently could, and should, be performing better than they currently are for Indigenous people with cancer in the NT, and
probably elsewhere in Australia. In the NT,
Indigenous people are more likely to be
diagnosed late and, once diagnosed, have a
lower chance of cure than non-Indigenous
people. The reasons for later diagnosis and
lower survival for Indigenous patients
should be identified and remedied.
This study has demonstrated that analysis
and reporting of cancer stage at diagnosis
and cancer survival can be used to assess the
performance of the NT health services in
providing cancer diagnosis and treatment
services to Indigenous people. Data sources
are available for the same purpose from
cancer registries in other States, but have
either not been analysed or are too limited
by inadequacy of identification of Indigenous people to be useful. These limitations
should be remedied as soon as possible so
that the performance of cancer services for
Indigenous Australians can be measured
and improved nationally and, on the evidence of our data, urgently.
279
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